R/R MM: Treating Patients with CNS Metastases Involvement

Opinion
Video

Panelists discuss how they approach treatment strategies and challenges for relapsed/refractory multiple myeloma patients with CNS involvement, sharing case details and preferences among available therapeutic options.

Video content above is promoted by the following;

  • Briefly discuss your case details and share your initial thoughts.
  • How are you treating patients with R/R MM with CNS metastases involvement?
  • Do you prefer one treatment option over others?
  • What are the challenges you are seeing in this patient population?
Recent Videos
Two experts are featured in this series.
Two experts are featured in this series.
Two experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Two experts are featured in this series.
Two experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
Early Response Rates Noted With Elranatamab/Iberdomide in R/R Multiple Myeloma

Early Response Rates Noted With Elranatamab/Iberdomide in R/R Multiple Myeloma

Kristi Rosa
December 6th 2025
Article

Results from the MagnetisMM-30 trial showed early ORR data with elranatamab/iberdomide in R/R multiple myeloma.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

The 2.5 year progression-free survival rate was 80.5% with cilta-cel for this population, suggesting a potential cure fraction.

Cilta-Cel Exhibits Long-Term Survival in Standard-Risk R/R Multiple Myeloma

Chris Ryan
December 6th 2025
Article

The 2.5 year progression-free survival rate was 80.5% with cilta-cel for this population, suggesting a potential cure fraction.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma

Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma

Tim Cortese
December 6th 2025
Article

Elevated LDH levels were associated with worse PFS and OS outcomes in patients with relapsed/refractory multiple myeloma treated with elranatamab.

Teclistamab shows promising real-world effectiveness for relapsed/refractory multiple myeloma, with high response rates and manageable safety profiles.

How Has Teclistamab Administration Translated Into Community MM Settings?

ONCOLOGY Staff
December 6th 2025
Article

Teclistamab shows promising real-world effectiveness for relapsed/refractory multiple myeloma, with high response rates and manageable safety profiles.